Publication
Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.
Umberto Capitanio, Axel Bex, Grant D Stewart, Alessandro Larcher, Francesco Montorsi
European urologyAug 14, 2026PMID 42601237doi:10.1016/j.eururo.2026.07.034 LetterpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 13, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260913-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Kidney Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.